“…Specifically, anti-GluR3 Ab's were found in some patients with various types of epilepsy, suffering primarily from non-inflammatory focal epilepsy (Wiendl et al, 2001), or from severe, early-onset and intractable seizures (Mantegazza et al, 2002). Further studies and findings suggested that anti-GluR3 Ab's may indeed play a pathogenic role in epilepsy, since they can: (a) bind brain cells and structures Whitney and McNamara, 2000;Frassoni et al, 2001;Bernasconi et al, 2002), (b) activate ionotropic GluR's and evoke ion currents, acting like a "novel" glutamate agonist (Twyman et al, 1995;Koustova et al, 2001), (c) kill neurons and glia cells via excitotoxicity-a fatal overactivation of the glutamate receptors Koustova et al, 2001), alike that caused by excess glutamate in various pathological situations (Olney, 1990;Choi, 1992), and (d) activate the destructive complement system within the central nervous system (CNS), causing at first death of astrocytes, and then death of neurons (He et al, 1998;Whitney and McNamara, 2000). In this context it is of interest to mention that the serial recruitment of all the complement factors in the CNS was recently shown to induce seizures (Xiong et al, 2003).…”